About the Authors

Aditi Gupta

Roles Conceptualization, Methodology, Writing – original draft, Writing – review & editing

agupta@kumc.edu

Affiliations The Kidney Institute, University of Kansas Medical Center, Kansas City, KS, United States of America, Division of Nephrology and Hypertension, University of Kansas Medical Center, Kansas City, KS, United States of America, Alzheimer’s Disease Center, University of Kansas Medical Center, Kansas City, KS, United States of America

Kevin Kennedy

Roles Formal analysis

Affiliation Kansas City Veterans Affairs, University of Kansas Medical Center, Kansas City, KS, United States of America

Jaime Perales-Puchalt

Roles Methodology, Writing – review & editing

Affiliations Alzheimer’s Disease Center, University of Kansas Medical Center, Kansas City, KS, United States of America, Department of Neurology, University of Kansas Medical Center, Kansas City, KS, United States of America

David Drew

Roles Writing – review & editing

Affiliation Division of Nephrology and Hypertension, Tufts Medical Center, Boston MA, United States of America

Srinivasan Beddhu

Roles Methodology, Writing – review & editing

Affiliation University of Utah, Salt Lake City, UT, United States of America

Mark Sarnak

Roles Methodology, Writing – review & editing

Affiliation Division of Nephrology and Hypertension, Tufts Medical Center, Boston MA, United States of America

Jeffrey Burns

Roles Methodology, Writing – review & editing

Affiliations Alzheimer’s Disease Center, University of Kansas Medical Center, Kansas City, KS, United States of America, Department of Neurology, University of Kansas Medical Center, Kansas City, KS, United States of America

the Alzheimer’s Disease Neuroimaging Initiative

A complete membership of the author group can be found in the Acknowledgments.

Competing Interests

The authors declare no conflict of interest that alters their adherence to PLOS ONE policies on sharing data and materials. AG has a consultancy agreement with Novartis Pharmaceuticals and has grant funding from Novartis and Veloxis Pharmaceuticals; none of which are relevant to the current manuscript.